Samsung Biologics, Foreign Investors Net Buy 85,643 Shares in Last 5 Days... Stock Price 829,000 KRW (+3.62%)

As of 1:31 PM on the 18th, Samsung Biologics is trading at 829,000 KRW, up 3.62% from the previous day. The trading volume is 178,096 shares, which is 83.43% of the previous day's volume. Samsung Biologics is known as the bio business holding company of the Samsung Group.

On August 12, Lee Dong-geon, a researcher at Shinhan Financial Investment, reflected an upward revision of the existing assumed production scale of Plant 4 from 180,000 liters to the actual expansion scale of 256,000 liters. With the expansion of Plant 4, the proportion of large-scale bioreactors will increase, and the share of commercialized pharmaceutical production is also expected to expand. The company's operating profit margin is also expected to rise to the mid-40% range in the future due to the continuous increase in batch numbers, and Lee set the target price for Samsung Biologics at 950,000 KRW.

Over the past five days, individual investors have net sold 83,161 shares of Samsung Biologics, while foreigners and institutions have net bought 85,643 shares and 10,305 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.